FXR activation downregulates SREBP-1c and its lipogenic targets, including FASN, SCD1, and ACC, thereby reducing fatty acid synthesis and triglyceride accumulation and protecting against hepatic steatosis.332. This evidence concerns the gene FASN and fatty liver disease.